08-30-2022, 09:32 AM
![[Image: c169b4ff844f55be16e23c31fdf2faf6.jpg]](https://www.img.in.th/images/c169b4ff844f55be16e23c31fdf2faf6.jpg)
Astra announces COVID-19 drug Evusheld trial results in severe illness and death
Asta Senneca Co. COVID-19 vaccine maker168xo autoResults of a phase 3 study of Evusheld to treat COVID-19 revealed found that it can prevent the occurrence of severe disease or death from all causes were clinically and statistically significant
The results of the trial published in The Lancet Respiratory Medicine show that it can prevent the development of severe disease. or death from all causes were clinically and statistically significant Compared to the placebo group treated with Evusheld in the early stages of disease, can lead to better results.
The Tackle trial studies participants who are outpatients with COVID-19. with mild to moderate symptoms lasting no more than 7 days. In addition, 90 percent of participants had underlying diseases and conditions at risk of severe infection with COVID-19. or an elderly person
Hugh Montgomory, Professor at the Department of Intensive Medicine University College London and lead researcher for Project Tackle will be successful in a wide But there are still many populations who are still at high risk of developing severe disease, such as the elderly, those with congenital diseases. and people with impaired immune systems so other methods Therefore it is necessary to prevent disease progression. and reduce the burden on the public health system especially with the emergence of various new species. continually Tackle trial shows that intramuscular injection of one dose of Evusheld can prevent the progression of COVID-19. to a severe stage The faster the drug is received, the more beneficial the treatment will be.”